These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6644705)

  • 1. Acetylator phenotype and the effect of dapsone in rheumatoid arthritis.
    Crook PR; Hortas C; Roberts EJ; Swinson DR; Mucklow JC; Shadforth MF
    J Rheumatol; 1983 Oct; 10(5):805-8. PubMed ID: 6644705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylator phenotype in rheumatoid arthritis.
    Ehrenfeld M; Zylber-Katz E; Levy M
    Isr J Med Sci; 1983 Apr; 19(4):368-70. PubMed ID: 6853137
    [No Abstract]   [Full Text] [Related]  

  • 3. Acetylator phenotypes in rheumatoid arthritis patients with or without adverse drug reactions to sodium-aurothiomalate or d-penicillamine.
    Rantapää Dahlqvist S; Mjörndal T
    Scand J Rheumatol; 1987; 16(4):235-9. PubMed ID: 3114874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylator phenotype, minimal maintenance dose and haemolytic effect of dapsone in dermatitis herpetiformis.
    Förström L; Mattila MJ; Mustakallio KK
    Ann Clin Res; 1974 Oct; 6(5):308-10. PubMed ID: 4447343
    [No Abstract]   [Full Text] [Related]  

  • 5. Varying distribution of acetylation phenotypes in RA patients with and without Sjögren's syndrome.
    Leden I; Hanson A; Melander A; Sturfelt G; Svensson B; Wàhlin-Boll E
    Scand J Rheumatol; 1981; 10(3):253-5. PubMed ID: 7291958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of relevance of the acetylator status on dapsone response in chronic autoimmune thrombocytopenic purpura.
    Le Louët H; Ruivart M; Bierling P; Duche JC; Godeau B
    Am J Hematol; 1999 Dec; 62(4):251-2. PubMed ID: 10589083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of rheumatoid arthritis with dapsone].
    Sonne M
    Ugeskr Laeger; 1983 Sep; 145(37):2847-8. PubMed ID: 6359616
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level.
    Guo R; Thormann W; Lauterberg B
    Chin Med J (Engl); 1996 Dec; 109(12):933-6. PubMed ID: 9275325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylation phenotype in rheumatoid arthritis.
    Oka M; Seppälä O
    Scand J Rheumatol; 1978; 7(1):29-30. PubMed ID: 675172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of rheumatoid polyarthritis with dapsone. A controlled study versus placebo].
    Job-Deslandre C; Menkès CJ
    Rev Rhum Mal Osteoartic; 1989 Mar; 56(4):313-6. PubMed ID: 2652273
    [No Abstract]   [Full Text] [Related]  

  • 11. Acetylator phenotyping: a comparison of the isoniazid and dapsone tests.
    Hanson A; Melander A; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1981; 20(3):233-4. PubMed ID: 7286042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylation of dapsone by human whole blood.
    Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM; Gharaibeh NS
    Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):18-22. PubMed ID: 8444513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus.
    Najim RA; Farid YY; Samad TA; Shihab SA
    East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
    Bluhm RE; Adedoyin A; McCarver DG; Branch RA
    Clin Pharmacol Ther; 1999 Jun; 65(6):598-605. PubMed ID: 10391665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylator phenotyping: the effect of ethanol on the dapsone test.
    Hutchings A; Monie RD; Spragg B; Routledge PA
    Br J Clin Pharmacol; 1984 Jul; 18(1):98-100. PubMed ID: 6743494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
    Khanna D; Park GS; Paulus HE; Simpson KM; Elashoff D; Cohen SB; Emery P; Dorrier C; Furst DE
    Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs.
    Palamanda JR; Hickman D; Ward A; Sim E; Romkes-Sparks M; Unadkat JD
    Drug Metab Dispos; 1995 Apr; 23(4):473-7. PubMed ID: 7600914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylator phenotype in Iraqi patients with atopic dermatitis.
    Najim RA; Al-Waiz MM; Al-Razzuqi RA
    Dermatol Online J; 2006 Dec; 12(7):1. PubMed ID: 17459287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.